National Cancer Institute (NCI): Prostatic Neoplasms trials

The registry lists 185 Prostatic Neoplasms studies with National Cancer Institute (NCI) as lead sponsor. 23 are open to participants now and 87 have results posted.

Early Phase 1 3Phase 1 49Phase 2 111Phase 3 5No phase 32(a study in two phases counts in both)

Studies

Page 1 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• IL-15 Superagonist With or Without Vaccine in Biochemically Recurrent Prostate Cancer After Previous Stereotactic Body Radiation TherapyRecruitingNCT07686380Phase 2
• Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate CancerRecruitingNCT07667400Phase 1/2
• Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active SurveillanceNot yet recruitingNCT07574541Phase 2
• Natural History Study of Early Life Exposures in Agriculture (ELEA)Enrolling by invitationNCT07328516
• The Vanguard Study: Testing a New Way to Screen for CancerRecruitingNCT06995898Not applicable
• Surface Electrical Stimulation for Urinary Incontinence in Men Treated for Prostate CancerRecruitingNCT06161506Phase 2
• Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering TherapyRecruitingNCT06096870Phase 2
• Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine CellsRecruitingNCT05691465Phase 2
• Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate TumorRecruitingNCT05616650Phase 2
• Prospective Monitoring of Subjects With Biochemically Recurrent Prostate Cancer Using 18FDCFPyLRecruitingNCT05588128
• A Phase II Study Evaluating T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine PDS01ADC in Localized High and Intermediate Risk Prostate Cancer Treated With Androgen Deprivation TherapyRecruitingNCT05361798Phase 2
• Precision-Based Genomics in Prostate CancerRecruitingNCT04706663
• Multiparametric Magnetic Resonance Imaging of the Prostate to Assess Disease Progression and Genomics in Patients Undergoing Active Surveillance for Prostate CancerRecruitingNCT04692675Not applicable
• A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate CancerRecruitingNCT04633252Phase 1/2
• Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary TumorsRecruitingNCT03866382Phase 2
• Men at High Genetic Risk for Prostate CancerRecruitingNCT03805919
• Profiling of Radiological Factors in Treatment and Outcomes in Prostate CancerRecruitingNCT03354416
• Care of the Prostate Cancer Patient and Prospective Procurement of Prostate Cancer TissueRecruitingNCT02594202
• Imaging Studies to Check the Local Response of Prostate Cancer to Radiation TherapyRecruitingNCT01834001
• Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic AnalysisRecruitingNCT01441089
• Collection of Blood From Patients With Prostate CancerRecruitingNCT00923221
• Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer StudiesRecruitingNCT00451022
• Collection of Blood From Patients With CancerRecruitingNCT00034216
• Treatment of Cancer-Related Bone Pain by Using Bone-Targeted Radiation-Based Therapy (Sn-117m-DTPA) in Patients With Prostate Cancer That Has Spread to BonesTerminatedNCT04616547Phase 2Results posted
• Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate GlandCompletedNCT04530552Phase 2Results posted
• Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIVActive, not recruitingNCT04514484Phase 1Results posted
• Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide TreatmentTerminatedNCT03531827Phase 2Results posted
• M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate CancerActive, not recruitingNCT03517969Phase 2Results posted
• Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)CompletedNCT03493945Phase 1/2Results posted
• Treatment of Castration Resistant Prostate Cancer Using Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy VaccinesCompletedNCT03481816Phase 1Results posted
• Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single Dose Administration Under Fasting Conditions in Prostate CancerTerminatedNCT03478904Phase 1Results posted
• The Effects of Castration on the Pharmacokinetics of Zolpidem After Single Dose Administration In Men With Prostate Cancer Undergoing Androgen Deprivation Therapy Compared to Normal Healthy FemalesTerminatedNCT03436745Phase 1Results posted
• Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy RadiotherapyCompletedNCT03388619Phase 1Results posted
• Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone MetastasisActive, not recruitingNCT03317392Phase 1/2Results posted
• Combination Immunotherapy in Biochemically Recurrent Prostate CancerCompletedNCT03315871Phase 2Results posted
• Prostate SBRT for Locally Recurrent Prostate Cancer After Prior RadiotherapyCompletedNCT03253744Phase 1Results posted
• PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by SurgeryCompletedNCT03218826Phase 1Results posted
• PROSTVAC in Combination With Nivolumab in Men With Prostate CancerCompletedNCT02933255Phase 1/2Results posted
• Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate CancerActive, not recruitingNCT02893917Phase 2Results posted
• Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung CancerTerminatedNCT02769962Phase 1/2Results posted
• Docetaxel and PROSTVAC for Metastatic Castration-Sensitive Prostate CancerCompletedNCT02649855Phase 2Results posted
• Prostvac in Patients With Biochemically Recurrent Prostate CancerCompletedNCT02649439Phase 2Results posted
• Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate CancerCompletedNCT02430480Phase 2Results posted
• Long-Term TARP Vaccination Using a Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Previously Vaccinated Men on NCI 09-C-0139CompletedNCT02362464Phase 2Results posted
• Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Men With Stage D0 Prostate CancerTerminatedNCT02362451Phase 2Results posted
• PROSTVAC (PSA-TRICOM) in Preventing Disease Progression in Patients With Localized Prostate Cancer Undergoing Active SurveillanceCompletedNCT02326805Phase 2Results posted
• Cognitive Testing of Tobacco Use Measurement Items for Administration With Cancer Patients and SurvivorsCompletedNCT02233842Results posted
• A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate CancerTerminatedNCT02203513Phase 2Results posted
• 18F-DCFBC PET/CT in Prostate CancerCompletedNCT02190279Early Phase 1Results posted
• Vaccine Plus Booster Shots in Men With Prostate Cancer Undergoing Treatment With Radical ProstatectomyCompletedNCT02153918Phase 2Results posted
• Pomegranate-Extract Pill in Preventing Tumor Growth in Patients With Localized Prostate Cancer Undergoing Active SurveillanceCompletedNCT02095145Phase 2Results posted
• Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate CancerCompletedNCT01875250Phase 2Results posted
• Gadoxetate Enhanced Imaging Study to Detect Prostate CancerCompletedNCT01867424Phase 2Results posted
• Enzalutamide With or Without Vaccine Therapy for Advanced Prostate CancerCompletedNCT01867333Phase 2Results posted
• Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate CancerCompletedNCT01683994Phase 1/2Results posted
• Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate CancerCompletedNCT01576172Phase 2Results posted
• AMG 386 and Abiraterone for Advanced Prostate CancerCompletedNCT01553188Phase 2Results posted
• Linsitinib in Treating Patients With Asymptomatic or Mildly Symptomatic Metastatic Prostate CancerCompletedNCT01533246Phase 2Results posted
• Tivantinib in Treating Patients With Metastatic Prostate CancerCompletedNCT01519414Phase 2Results posted
• Metformin Hydrochloride in Treating Patients With Prostate Cancer Undergoing SurgeryCompletedNCT01433913Phase 2Results posted
• MR Image Guided Therapy in Prostate CancerCompletedNCT01377753Phase 2Results posted
• Cholecalciferol and Genistein Before Surgery in Treating Patients With Early Stage Prostate CancerCompletedNCT01325311Phase 2Results posted
• Saracatinib in Treating Patients With Prostate CancerTerminatedNCT01267266Phase 2Results posted
• Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With DocetaxelCompletedNCT01260688Phase 2Results posted
• Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate CancerCompletedNCT01251861Phase 2Results posted
• F-18 Sodium Fluoride in Prostate CancerCompletedNCT01240551Phase 2Results posted
• Bicalutamide and RO4929097 in Treating Patients With Previously Treated Prostate CancerTerminatedNCT01200810Phase 2Results posted
• Leuprolide Acetate or Goserelin Acetate With or Without Vismodegib Followed by Surgery in Treating Patients With Locally Advanced Prostate CancerTerminatedNCT01163084Phase 1/2Results posted
• Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate CancerTerminatedNCT01145508Phase 2Results posted
• Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate CancerCompletedNCT01120236Phase 2Results posted
• A Phase I/II Study of TRC105 in Metastatic Castrate Resistant Prostate Cancer (CRPC)CompletedNCT01090765Phase 1/2Results posted
• Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate CancerCompletedNCT01026623Phase 1/2Results posted
• A Pilot Study of Vaccination With Epitope-Enhanced TARP Peptide and TARP Peptide-Pulsed Dendritic Cells in the Treatment of Stage D0 Prostate CancerCompletedNCT00972309Phase 1Results posted
• A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate CancerCompletedNCT00942578Phase 2Results posted
• Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract CancerCompletedNCT00942331Phase 3Results posted
• Fluorine F 18 Sodium Fluoride Positron Emission Tomography in Evaluating Response to Dasatinib in Patients With Prostate Cancer and Bone MetastasesCompletedNCT00936975Phase 2Results posted
• Positron Emission Tomography and Magnetic Resonance Imaging for Prostate CancerCompletedNCT00924313Phase 1/2Results posted
• A Study of Patients Receiving High-Dose Rate BrachytherapyCompletedNCT00924027Phase 2Results posted
• R-(-)-Gossypol and Androgen Ablation Therapy in Treating Patients With Newly Diagnosed Metastatic Prostate CancerCompletedNCT00666666Phase 2Results posted
• Satraplatin and Prednisone to Treat Prostate CancerCompletedNCT00634647Phase 2Results posted
• Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate CancerCompletedNCT00589472Phase 2Results posted
• Docetaxel and Prednisone With or Without Cediranib in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone TherapyTerminatedNCT00527124Phase 2Results posted
• AZD0530 in Treating Patients With Prostate Cancer That Did Not Respond to Hormone TherapyCompletedNCT00513071Phase 2Results posted
• Pazopanib Hydrochloride With or Without Bicalutamide in Treating Patients With Prostate Cancer That Did Not Respond to Hormone TherapyCompletedNCT00486642Phase 2Results posted
• Pazopanib Hydrochloride After Leuprolide Acetate or Goserelin Acetate in Treating Patients With Relapsed Prostate CancerCompletedNCT00454571Phase 2Results posted
• Lycopene in Treating Patients Undergoing Radical Prostatectomy for Prostate CancerCompletedNCT00450749Phase 2Results posted
• 153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate CancerCompletedNCT00450619Phase 2Results posted
• Vaccine Therapy With PROSTVAC/TRICOM and Flutamide Versus Flutamide Alone to Treat Prostate CancerCompletedNCT00450463Phase 2Results posted
• Finasteride in Treating Patients With Stage II Prostate Cancer Who Are Undergoing SurgeryCompletedNCT00438464Phase 2Results posted
• AZD2171 to Treat Prostate CancerCompletedNCT00436956Phase 2Results posted
• Tandutinib in Treating Patients With Progressive Prostate Cancer and Bone MetastasesCompletedNCT00390468Phase 2Results posted
• Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone TherapyCompletedNCT00337077Phase 2Results posted
• Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and ChemotherapyCompletedNCT00331344Phase 1/2Results posted
• Vorinostat in Treating Patients With Progressive Metastatic Prostate CancerCompletedNCT00330161Phase 2Results posted
• Intensity Modulated Radiation Therapy for Prostate CancerCompletedNCT00214422Early Phase 1Results posted
• Phase I Study of Intensity Modulated Radiation Therapy for Prostate CancerTerminatedNCT00124917Phase 1Results posted
• Cilengitide in Treating Patients With Prostate CancerCompletedNCT00121238Phase 2Results posted
• 17-AAG in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone TherapyCompletedNCT00118092Phase 2Results posted
• Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone TherapyCompletedNCT00110214Phase 3Results posted
• A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate CancerCompletedNCT00108732Phase 2Results posted